| Title |
Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
|
|---|---|
| Published in |
PLOS ONE, March 2013
|
| DOI | 10.1371/journal.pone.0060095 |
| Pubmed ID | |
| Authors |
Heiner K. Berthold, Nabil G. Seidah, Suzanne Benjannet, Ioanna Gouni-Berthold |
| Abstract |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted inhibitor of the low-density lipoprotein (LDL) receptor and an important regulator of LDL metabolism. Elevated PCSK9 levels have been associated with cardiovascular risk. The purpose of this study was to investigate how ezetimibe and simvastatin, alone and in combination, affect PCSK9 circulating concentrations. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 2 | 4% |
| Japan | 1 | 2% |
| Finland | 1 | 2% |
| Canada | 1 | 2% |
| Unknown | 50 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 22% |
| Researcher | 8 | 15% |
| Student > Bachelor | 8 | 15% |
| Student > Master | 6 | 11% |
| Other | 4 | 7% |
| Other | 9 | 16% |
| Unknown | 8 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 33% |
| Agricultural and Biological Sciences | 11 | 20% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Business, Management and Accounting | 2 | 4% |
| Other | 3 | 5% |
| Unknown | 10 | 18% |